JP2005506290A - 癌および他の増殖性疾患を処置するための複素環式誘導体 - Google Patents

癌および他の増殖性疾患を処置するための複素環式誘導体 Download PDF

Info

Publication number
JP2005506290A
JP2005506290A JP2002570969A JP2002570969A JP2005506290A JP 2005506290 A JP2005506290 A JP 2005506290A JP 2002570969 A JP2002570969 A JP 2002570969A JP 2002570969 A JP2002570969 A JP 2002570969A JP 2005506290 A JP2005506290 A JP 2005506290A
Authority
JP
Japan
Prior art keywords
substituted
adamantyl
thiazolidinedione
cancer
residue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002570969A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005506290A5 (cg-RX-API-DMAC7.html
Inventor
マグナス ファール，
フセイン エイ． アル−シャンマ，
アンドレア ファンジュル，
デイビッド ピー． エム． プレイネット，
ライル ダブリュー． スプルース，
トーステン アール． ウィーマン，
ジェイソン ビー． イバーラ，
キャサリン タチュジアン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Incyte San Diego Inc
Original Assignee
Maxia Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Maxia Pharmaceuticals Inc filed Critical Maxia Pharmaceuticals Inc
Publication of JP2005506290A publication Critical patent/JP2005506290A/ja
Publication of JP2005506290A5 publication Critical patent/JP2005506290A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/34—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2002570969A 2001-03-07 2002-03-07 癌および他の増殖性疾患を処置するための複素環式誘導体 Pending JP2005506290A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27475101P 2001-03-07 2001-03-07
PCT/US2002/007001 WO2002072009A2 (en) 2001-03-07 2002-03-07 Heterocyclic derivatives for the treatment of cancer and other proliferative diseases

Publications (2)

Publication Number Publication Date
JP2005506290A true JP2005506290A (ja) 2005-03-03
JP2005506290A5 JP2005506290A5 (cg-RX-API-DMAC7.html) 2005-12-22

Family

ID=23049469

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002570969A Pending JP2005506290A (ja) 2001-03-07 2002-03-07 癌および他の増殖性疾患を処置するための複素環式誘導体

Country Status (12)

Country Link
US (1) US7153875B2 (cg-RX-API-DMAC7.html)
EP (1) EP1385465A4 (cg-RX-API-DMAC7.html)
JP (1) JP2005506290A (cg-RX-API-DMAC7.html)
AU (1) AU2002252227A1 (cg-RX-API-DMAC7.html)
BR (1) BR0207846A (cg-RX-API-DMAC7.html)
CA (1) CA2440184A1 (cg-RX-API-DMAC7.html)
EA (1) EA200300982A1 (cg-RX-API-DMAC7.html)
IL (1) IL157740A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA03008117A (cg-RX-API-DMAC7.html)
NO (1) NO20033883L (cg-RX-API-DMAC7.html)
PL (1) PL373912A1 (cg-RX-API-DMAC7.html)
WO (1) WO2002072009A2 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008534643A (ja) * 2005-04-08 2008-08-28 ガルデルマ・リサーチ・アンド・デヴェロップメント ６−［３−（１−アダマンチル）−４−メトキシフェニル］−２−ナフトエ酸の合成方法

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA74344C2 (uk) 1999-08-31 2005-12-15 Максіа Фармасьютікалз, Інк. Бензилідентіазолідиндіони і їх аналоги та їх застосування для лікування діабету
MXPA03008117A (es) 2001-03-07 2004-11-12 Incyte San Diego Inc Derivados heterociclicos para el tratamiento del cancer y otras enfermedades proliferativas.
CA2473156A1 (en) * 2001-03-08 2002-09-19 Incyte San Diego, Inc. Rxr activating molecules
WO2003016267A1 (en) * 2001-08-17 2003-02-27 Incyte San Diego Incorporated Oxime derivatives for the treatment of dyslipidemia and hypercholesteremia
AU2002352706A1 (en) * 2001-11-15 2003-06-10 Maxia Pharmaceuticals, Inc. N-substituted heterocycles for the treatment of hypercholesteremia, dyslipidemia and other metabolic disorders, cancer, and other diseases
WO2003048101A1 (en) 2001-11-30 2003-06-12 The Burnham Institute Induction of apoptosis in cancer cells
US7102000B2 (en) * 2002-03-08 2006-09-05 Incyte San Diego Inc. Heterocyclic amide derivatives for the treatment of diabetes and other diseases
US7196108B2 (en) * 2002-03-08 2007-03-27 Incyte San Diego Inc. Bicyclic heterocycles for the treatment of diabetes and other diseases
WO2004093871A1 (en) * 2003-03-27 2004-11-04 Lankenau Institute For Medical Research Novel methods for the treatment of cancer
FR2856401B1 (fr) * 2003-06-20 2010-02-12 Galderma Res & Dev Nouveaux composes modulateurs des recepteurs de type ppargamma et leur utilisation dans des compositions cosmetiques ou pharmaceutiques
DE10351744A1 (de) * 2003-10-31 2005-06-16 Schering Ag Thiazolidinone, deren Herstellung und Verwendung als Arzneimittel
US7122700B2 (en) 2004-07-30 2006-10-17 Xerox Corporation Arylamine processes
FR2884248B1 (fr) * 2005-04-08 2007-05-18 Galderma Res & Dev Nouveau procede de preparation de l'acide 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphtoique
KR100814109B1 (ko) * 2006-01-09 2008-03-14 한국생명공학연구원 로다닌 유도체, 이의 제조방법 및 이를 유효성분으로함유하는 약학적 조성물
TW200815429A (en) * 2006-04-11 2008-04-01 Smithkline Beecham Corp Thiazolidinedione derivatives as PI3 kinase inhibitors
US20080255115A1 (en) * 2007-04-11 2008-10-16 Michael Gerard Darcy Thiazolidinedione derivatives as pi3 kinase inhibitors
US7592342B2 (en) * 2007-05-10 2009-09-22 Smithkline Beecham Corporation Quinoxaline derivatives as PI3 kinase inhibitors
PE20090717A1 (es) 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
KR20100108346A (ko) 2007-11-21 2010-10-06 디코드 제네틱스 이에이치에프 폐 및 심장혈관 질병의 치료를 위한 바이아릴 ｐｄｅ4 억제제
AU2008326381B2 (en) * 2007-11-21 2014-10-23 Decode Genetics Ehf Biaryl PDE4 inhibitors for treating inflammation
CN102558088A (zh) * 2010-12-31 2012-07-11 中国科学院上海药物研究所 联苯亚甲基-2-硫代-4-噻唑酮类化合物及其制备方法和用途
JP2024546175A (ja) * 2021-12-21 2024-12-17 メディフィック インク 置換されたチアゾリジンジオン誘導体化合物およびこれを含む癌の予防または治療用の薬学的組成物
US12115148B1 (en) 2024-05-10 2024-10-15 Imam Mohammad Ibn Saud Islamic University 3-(2-(1,3-dioxoisoindolin-2-yl)ethyl)-5-(2-hydroxy-5-nitrobenzylidene)thiazolidine-2,4-dione as a potential antitumor and apoptotic inducer

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4051842A (en) 1975-09-15 1977-10-04 International Medical Corporation Electrode and interfacing pad for electrical physiological systems
DE2626348C3 (de) 1976-06-11 1980-01-31 Siemens Ag, 1000 Berlin Und 8000 Muenchen Implantierbare Dosiereinrichtung
JPS5538359A (en) 1978-09-12 1980-03-17 Hamari Yakuhin Kogyo Kk Preparation of 2-(3-benzoylphenyl)-propionic acid
US4383529A (en) 1980-11-03 1983-05-17 Wescor, Inc. Iontophoretic electrode device, method and gel insert
IL72684A (en) 1984-08-14 1989-02-28 Israel State Pharmaceutical compositions for controlled transdermal delivery of cholinergic or anticholinergic basic drugs
US4668506A (en) 1985-08-16 1987-05-26 Bausch & Lomb Incorporated Sustained-release formulation containing and amino acid polymer
US4931279A (en) 1985-08-16 1990-06-05 Bausch & Lomb Incorporated Sustained release formulation containing an ion-exchange resin
US4713244A (en) 1985-08-16 1987-12-15 Bausch & Lomb Incorporated Sustained-release formulation containing an amino acid polymer with a lower alkyl (C1 -C4) polar solvent
CA1325222C (en) 1985-08-23 1993-12-14 Lederle (Japan), Ltd. Process for producing 4-biphenylylacetic acid
JP2539504B2 (ja) 1987-03-11 1996-10-02 鐘淵化学工業株式会社 ヒドロキシスチレン誘導体
FI91869C (fi) * 1987-03-18 1994-08-25 Tanabe Seiyaku Co Menetelmä antidiabeettisena aineena käytettävien bensoksatsolijohdannaisten valmistamiseksi
US5330998A (en) 1988-03-08 1994-07-19 Pfizer Inc. Thiazolidinedione derivatives as hypoglycemic agents
US5223522A (en) 1988-03-08 1993-06-29 Pfizer Inc. Thiazolidinedione hypoglycemic agents
IE62214B1 (en) 1988-05-25 1995-01-11 Warner Lambert Co Arylmethylenyl derivatives of thiazolidinones, imidazolidinones and oxazolidinones useful as antiallergy agents and antiinflammatory agents
DK0595868T3 (da) 1991-07-22 1999-08-09 Pfizer Fremgangsmåde til fremstilling af (S)-4-[3-(5-methyl-2-phenyl-4-oxazolyl)-1-hydroxypropyl]-brombenzen
EP0983991B1 (en) 1992-04-22 2003-12-17 Ligand Pharmaceuticals, Inc. Compounds having selectivity for retinoid x receptors
US5780676A (en) 1992-04-22 1998-07-14 Ligand Pharmaceuticals Incorporated Compounds having selective activity for Retinoid X Receptors, and means for modulation of processes mediated by Retinoid X Receptors
ZA936492B (en) 1992-09-10 1995-03-02 Lilly Co Eli Compounds useful as hypoglycemic agents and for treating Alzheimer's disease.
CA2149882A1 (en) 1992-11-25 1994-06-09 Magnus Pfahl Rxr homodimer formation and bridged bicyclic aromatic compounds and their use in modulating gene expression
DE69508568T2 (de) 1994-02-17 1999-10-21 American Home Products Corp., Madison Substituierte biphenyl-derivate mit phosphodiesterase inhibierender wirkung
US5691376A (en) 1994-02-17 1997-11-25 American Home Products Corporation Substituted biphenyl derivatives
JPH09136877A (ja) 1995-06-16 1997-05-27 Takeda Chem Ind Ltd 複素環化合物、その製造法及び用途
CA2223489A1 (en) 1995-07-17 1997-02-06 Joseph A. Fontana Method for treating cancer using ahpn
JP2000511875A (ja) 1996-06-19 2000-09-12 ドクター・レディーズ・リサーチ・ファウンデーション 抗糖尿病活性を増強されたトログリタゾンの新規な多形型及びそれらの製造方法
ES2231877T3 (es) 1996-07-08 2005-05-16 GALDERMA RESEARCH & DEVELOPMENT, S.N.C. Derivados de adamantillo inductores de apoptosis y su utilizacion como agentes anticancerigenos.
WO1999009965A2 (en) 1997-08-21 1999-03-04 Takeda Chemical Industries, Ltd. Anti-inflammatory agent
US5972986A (en) * 1997-10-14 1999-10-26 G.D. Searle & Co. Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia
JP4398585B2 (ja) 1997-11-12 2010-01-13 有限会社ケムフィズ レチノイドレセプター作用剤
US6262044B1 (en) * 1998-03-12 2001-07-17 Novo Nordisk A/S Modulators of protein tyrosine phosphatases (PTPASES)
US6331633B1 (en) 1998-05-08 2001-12-18 Calyx Therapeutics Inc. Heterocyclic analogs of diphenylethylene compounds
IL141456A0 (en) 1998-08-21 2002-03-10 Viropharma Inc Rhodanine derivatives and pharmaceutical compositions containing the same
WO2000018748A1 (en) 1998-09-30 2000-04-06 Roche Diagnostics Gmbh Rhodanine derivatives for the treatment and prevention of metabolic bone disorders
WO2000032598A1 (en) 1998-12-04 2000-06-08 Structural Bioinformatics Inc. Methods and compositions for treating inflammatory diseases utilizing inhibitors of tumor necrosis factor activity
WO2000063196A1 (en) 1999-04-20 2000-10-26 Novo Nordisk A/S New compounds, their preparation and use
US6462032B1 (en) 1999-05-04 2002-10-08 Wyeth Cyclic regimens utilizing indoline derivatives
UA74344C2 (uk) 1999-08-31 2005-12-15 Максіа Фармасьютікалз, Інк. Бензилідентіазолідиндіони і їх аналоги та їх застосування для лікування діабету
PT1142885E (pt) 1999-11-12 2007-02-28 Fujimoto Brothers Co Ltd Derivados de 2-(n-cianoimino)tiazolidin-4-ona
FR2812876B1 (fr) 2000-08-08 2002-09-27 Galderma Res & Dev Nouveaux composes bi-aromatiques activateurs des recepteurs de type ppar-gamma et leur utilisation dans des compositions cosmetiques ou pharmaceutiques
MXPA03008117A (es) 2001-03-07 2004-11-12 Incyte San Diego Inc Derivados heterociclicos para el tratamiento del cancer y otras enfermedades proliferativas.
CA2473156A1 (en) * 2001-03-08 2002-09-19 Incyte San Diego, Inc. Rxr activating molecules
ES2244772T3 (es) 2001-03-14 2005-12-16 Eli Lilly And Company Moduladores de receptores de retinoides x.
ES2331561T3 (es) 2001-04-04 2010-01-08 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Terapia combinada que comprende inhibidores de la reabsorcion de glucosa y moduladores de receptores de retinoides x.
WO2003016267A1 (en) * 2001-08-17 2003-02-27 Incyte San Diego Incorporated Oxime derivatives for the treatment of dyslipidemia and hypercholesteremia
AU2002352706A1 (en) * 2001-11-15 2003-06-10 Maxia Pharmaceuticals, Inc. N-substituted heterocycles for the treatment of hypercholesteremia, dyslipidemia and other metabolic disorders, cancer, and other diseases
AR037714A1 (es) * 2001-12-06 2004-12-01 Maxia Pharmaceuticals Inc Derivados de tiazolidinona y oxazolidinona 2-sustituidos para la inhibicion de fosfatasas y el tratamiento de cancer
US7102000B2 (en) * 2002-03-08 2006-09-05 Incyte San Diego Inc. Heterocyclic amide derivatives for the treatment of diabetes and other diseases
US7196108B2 (en) * 2002-03-08 2007-03-27 Incyte San Diego Inc. Bicyclic heterocycles for the treatment of diabetes and other diseases
RU2401836C2 (ru) * 2003-06-20 2010-10-20 Галдерма Ресерч энд Девелопмент, С.Н.С. НОВЫЕ СОЕДИНЕНИЯ, КОТОРЫЕ МОДУЛИРУЮТ РЕЦЕПТОРЫ ТИПА PPARγ, И ИХ ПРИМЕНЕНИЕ В КОСМЕТИЧЕСКИХ И ФАРМАЦЕВТИЧЕСКИХ КОМПОЗИЦИЯХ

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008534643A (ja) * 2005-04-08 2008-08-28 ガルデルマ・リサーチ・アンド・デヴェロップメント ６−［３−（１−アダマンチル）−４−メトキシフェニル］−２−ナフトエ酸の合成方法

Also Published As

Publication number Publication date
IL157740A0 (en) 2004-03-28
NO20033883L (no) 2003-11-05
WO2002072009A3 (en) 2003-10-16
EP1385465A2 (en) 2004-02-04
EP1385465A4 (en) 2005-09-07
PL373912A1 (en) 2005-09-19
US20020143182A1 (en) 2002-10-03
US7153875B2 (en) 2006-12-26
EA200300982A1 (ru) 2004-12-30
CA2440184A1 (en) 2002-09-19
MXPA03008117A (es) 2004-11-12
AU2002252227A1 (en) 2002-09-24
WO2002072009A2 (en) 2002-09-19
NO20033883D0 (no) 2003-09-02
BR0207846A (pt) 2005-09-13

Similar Documents

Publication Publication Date Title
JP2005506290A (ja) 癌および他の増殖性疾患を処置するための複素環式誘導体
US7071218B2 (en) N-substituted heterocycles for the treatment of hypercholesteremia, dyslipidemia and other metabolic disorders; cancer, and other diseases
EP1214304B1 (en) Benzylidene-thiazolidinediones and analogues and their use in the treatment of diabetes
US20040097566A1 (en) 2-Substituted thiazolidinone and oxazolidinone derivatives for the inhibition of phosphatases and the treatment of cancer
US20040034004A1 (en) Bicyclic heterocycles for the treatment of diabetes and other diseases
JP2005530705A (ja) 糖尿病および他の疾患を治療するための複素環アミド誘導体
US20050038098A1 (en) Substituted dihydronaphthalene and isochroman compounds for the treatment of metabolic disorders, cancer and other diseases
US20050014767A1 (en) Benzoxazole, benzothiazole, and benzimidazole derivatives for the treatment of cancer and other diseases
JP2001058992A (ja) ベンゾアゼピン誘導体、その製造法および用途
EP1593677A2 (en) Benzylidene-thiazolidinediones and analogues and their use in the treatment of diabetes
HK1047591B (en) Benzylidene-thiazolidinediones and analogues and their use in the treatment of diabetes

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050307

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050307

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20081114

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090416